196,372 research outputs found

    Muovi uusien liiketoimintamahdollisuuksien avaajana

    No full text
    EU:n ”pillikielto” eli kertakäyttömuovijätettä rajoittava direktiivi on kuuma keskustelunaihe, jota myös M-Brainin asiantuntijat ovat seuranneet aktiivisesti. Se kytkeytyy yleiseen huoleen maailman merien roskaantumisesta. Joidenkin arvioiden mukaan valtamerissä on yli 5 triljoonaa muovikappaletta, ja joka vuosi mereen päätyy 5-13 miljoonaa tonnia muovia. Valtaosa, noin 86 prosenttia, EU:n rannoille ajautuvasta roskasta on kertakäyttöisiä muovituotteita

    Muovi uusien liiketoimintamahdollisuuksien avaajana

    No full text
    EU:n ”pillikielto” eli kertakäyttömuovijätettä rajoittava direktiivi on kuuma keskustelunaihe, jota myös M-Brainin asiantuntijat ovat seuranneet aktiivisesti. Se kytkeytyy yleiseen huoleen maailman merien roskaantumisesta. Joidenkin arvioiden mukaan valtamerissä on yli 5 triljoonaa muovikappaletta, ja joka vuosi mereen päätyy 5-13 miljoonaa tonnia muovia. Valtaosa, noin 86 prosenttia, EU:n rannoille ajautuvasta roskasta on kertakäyttöisiä muovituotteita

    Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012

    No full text
    This paper is meant to provide guidance to anyone wishing to write a neurological guideline for diagnosis or treatment, and is directed at the Scientist Panels and task forces of the European Federation of Neurological Societies (EFNS). It substitutes the previous guidance paper from 2004. It contains several new aspects: the guidance is now based on a change of the grading system for evidence and for the resulting recommendations, and has adopted The Grading of Recommendations, Assessment, Development and Evaluation system (GRADE). The process of grading the quality of evidence and strength of recommendations can now be improved and made more transparent. The task forces embarking on the development of a guideline must now make clearer and more transparent choices about outcomes considered most relevant when searching the literature and evaluating their findings. Thus, the outcomes chosen will be more critical, more patient-oriented and easier to translate into simple recommendations...

    AAN-EFNS guidelines on trigeminal neuralgia management

    No full text
    Several issues regarding diagnosis, pharmacological treatment, and surgical treatment of trigeminal neuralgia (TN) are still unsettled. The American Academy of Neurology and the European Federation of Neurological Societies launched a joint Task Force to prepare general guidelines for the management of this condition. After systematic review of the literature the Task Force came to a series of evidence-based recommendations. In patients with TN MRI may be considered to identify patients with structural causes. The presence of trigeminal sensory deficits, bilateral involvement, and abnormal trigeminal reflexes should be considered useful to disclose symptomatic TN, whereas younger age of onset, involvement of the first division, unresponsiveness to treatment and abnormal trigeminal evoked potentials are not useful in distinguishing symptomatic from classic TN. Carbamazepine (stronger evidence) or oxcarbazepine (better tolerability) should be offered as first-line treatment for pain control. For patients with TN refractory to medical therapy early surgical therapy may be considered. Gasserian ganglion percutaneous techniques, gamma knife and microvascular decompression may be considered. Microvascular decompression may be considered over other surgical techniques to provide the longest duration of pain freedom. The role of surgery versus pharmacotherapy in the management of TN in patients with multiple sclerosis remains uncertain. © 2008 The Author(s)
    corecore